Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Centogene strategic collaboration with Lifera
We are advising Centogene on its joint venture with and convertible debt investment by Lifera
Noile-Immune Biotech ¥3.1 billion global IPO
The shares are listed on the Tokyo Stock Exchange
IDEAYA Biosciences $250 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
ATI Physical Therapy $100 million convertibles offering and recapitalization
We advised an ad hoc group of term lenders in connection with the transaction
Editas Medicine $125 million follow-on offering
The stock is listed on the Nasdaq Global Select Market
Cutia Therapeutics HK$412.9 million IPO
We advised Cutia on its IPO and HKEX listing
Tricida chapter 11 liquidation
We advised an ad hoc group of noteholders in connection with Tricida’s chapter 11 proceedings
Akoya Biosciences $50 million follow-on offering
The stock is listed on Nasdaq
Ionis Pharmaceuticals $575 million convertible senior notes offering
The 1.75% convertible senior notes are due 2028
LifeScan Global refinancing and amendment to credit facilities
We advised an ad hoc group of term lenders in connection with the transaction